Pande: There are currently fewer than 10,000 active pharmaceutical drugs
Vijay Pande · AI is Industrializing Discovery · Nov 21, 2019 · at 12:28
This episode carries Vijay Pande's own address, with nobody on the show putting questions to them. It still counts as said, and it is kept out of every score on their page.
Vijay Pande, Andreessen Horowitz General Partner, explains why machine learning models for drug discovery cannot rely on massive training datasets like computer vision models.
0:00 / 0:01exact quote · 1.4s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“We don't even have 10,000 active drugs.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Vijay Pande
Pande: Cancer could easily not exist in 10 years
“Cancer could easily just not exist in 10 years, and that's due to this change in how we think about things, and there's all these things on the back end.”
Vijay Pande: Compute costs will fall a million-fold over 20 years
“The nice thing about the exponentials is that, you know, things will go down a factor of a thousand, like, every 10 years on the Moore's Law side, and we'll continue to see that. So, a thousand, maybe in 20 years, a million, you know, a thousand times a thousa…”
Pande: Healthcare AI needs a 10x improvement threshold to overcome stigma
“Yeah, so I think the bar is different. This might be the magic has to get to 10 X. Mm-hmm. Something where 10% is probably within noise and without doubt or something like that, but 10 X is kind of the thing where, like, okay, okay. We have to think of things …”
Pande: Healthcare service providers will eventually transition into AI companies
“Well, you can imagine a services company that's providing some sort of healthcare service. It's training AI with its workers. And then the easy things, which are probably the boring things anyways, AI starts to do. And then the more interesting, complicated th…”
Pande: FDA rejects new drugs that are cheaper but equal in efficacy
“If you had a drug that was as good as the best drug, but cheaper, That still can't get that won't go by the FDA because they actually has to be better than the last drug, even if it's not better scientifically, but it's better in other ways.”